Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHEREXA trial of pertuzumab added to trastuzumab plus capecitabine in HER2-positive metastatic breast cancer
NL-OMON41586Phase 3Active, not recruiting
- Sponsor
- Covance
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing trastuzumab + capecitabine with pertuzumab + trastuzumab + capecitabine (2 arms). Primary endpoint: Progression-free survival. Started Sep 2011; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON41586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41586.